Dr. Sebastian Meier-Ewert is a biotech entrepreneur with extensive experience in translational drug discovery. 

He conducted his doctoral research at the Imperial Cancer Research Fund in London and the Max Planck Institute for Molecular Genetics in Berlin. Dr. Meier-Ewert has co-founded several biotechnology companies, including iOmx Therapeutics, GPC Biotech, and ROSCUE Therapeutics. His focus lies in translating scientific discoveries into novel drug candidates.

From 2012 to 2016, he served as Managing Director at MPM Capital, a U.S.-based venture capital firm specializing in breakthrough medicines. He is currently the CEO of ROSCUE Therapeutics, a company dedicated to developing next-generation ferroptosis-based therapies.